Researcher
Kathleen Van Asten
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From2 Apr 2013 → 15 Apr 2016
Publications
1 - 8 of 8
- Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients(2016)
Authors: Anneleen Lintermans, Kathleen Van Asten, Lynn Jongen, Annouschka Laenen, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven
Pages: 31 - 6 - Withdrawal of exogenous hormones affects prognostic multigene signature results in early lumina! breast cancer(2016)
Authors: Lynn Jongen, P De Vries, Kathleen Van Asten, A Lintermans, A Laenen, Hans Wildiers, Beppe Floris, Patrick Neven
- Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients(2016)
Authors: Anneleen Lintermans, Kathleen Van Asten, Lynn Jongen, Annouschka Laenen, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven
Pages: 31 - 36 - The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer(2015)
Authors: Kathleen Van Asten, Kevin Punie, Lynn Jongen, Hans Wildiers, Patrick Neven
Pages: 31 - Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens(2014)
Authors: Anneleen Lintermans, Dirk Vanderschueren, Johan Verhaeghe, Kathleen Van Asten, Annouschka Laenen, Robert Paridaens, Jaak Billen, Steven Pauwels, Pieter Vermeersch, Hans Wildiers, et al.
Pages: 2925 - 2931 - A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI(2014)
Authors: Anneleen Lintermans, Kathleen Van Asten, Hans Wildiers, Annouschka Laenen, Robert Paridaens, Caroline Weltens, Johan Verhaeghe, Dirk Vanderschueren, Ann Smeets, Erik Van Limbergen, et al.
Pages: 109 - 116 - 29p * a negative progesterone receptor in luminal her-2 negative breast cancer by age at diagnosis: 10 years follow-up(2014)
Authors: S Olbrecht, Kathleen Van Asten, Annouschka Laenen, C Remmerie, Hans Wildiers, Beppe Floris, Rose Christiaens, Ignace Vergote, Patrick Neven, BELGIUM MBC (Multidiscplinary Breast Centre
Pages: 10 - 10 - Aromatase inhibitors in the breast cancer clinic: focus on exemestane(2014)
Authors: Kathleen Van Asten, Patrick Neven, Anneleen Lintermans, Hans Wildiers, Robert Paridaens
Pages: R31 - R49